Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Painreform Ltd (PRFX)

Painreform Ltd (PRFX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 462
  • Shares Outstanding, K 145
  • Annual Sales, $ 0 K
  • Annual Income, $ -9,340 K
  • EBIT $ -6 M
  • EBITDA $ -10 M
  • 60-Month Beta 0.56
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.73 +71.95%
on 11/01/24
7.28 -59.20%
on 11/19/24
-0.27 (-8.33%)
since 10/22/24
3-Month
1.73 +71.95%
on 11/01/24
7.44 -60.07%
on 09/06/24
-3.46 (-53.79%)
since 08/22/24
52-Week
1.73 +71.95%
on 11/01/24
80.64 -96.32%
on 12/28/23
-48.63 (-94.24%)
since 11/22/23

Most Recent Stories

More News
PainReform Ltd. Reports Partial Topline Data from Phase 3 Trial of PRF-110 for Post-Surgical Pain Management

PainReform reports positive Phase 3 trial findings for PRF-110 in postoperative pain but faces data inconsistencies for key metrics.Quiver AI SummaryPainReform Ltd. announced the receipt of partial topline...

PRFX : 2.97 (-7.19%)
PainReform to Present at the Microcap Conference in Atlantic City

Tel Aviv, Israel--(Newsfile Corp. - January 22, 2024) - PainReform Ltd. (NASDAQ: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...

PRFX : 2.97 (-7.19%)
PainReform to Present at The Noble Capital Markets' Eighteenth Annual Investor Conference on April 20th

TEL AVIV, Israel, April 12, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company focused on the...

PRFX : 2.97 (-7.19%)
PainReform to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th

TEL AVIV, Israel, March 21, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty...

PRFX : 2.97 (-7.19%)
PainReform Provides Year-End Business Update; on Track to Commence Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief in the Second Half of 2022

TEL AVIV, Israel, March 17, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty...

PRFX : 2.97 (-7.19%)
PainReform CEO to Participate in the Benzinga All Access Event on December 16th

TEL AVIV, Israel, Dec. 14, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty...

PRFX : 2.97 (-7.19%)
PainReform Provides Business Update for the Third Quarter of 2021

Reports continued progress towards commencing Phase 3 clinical trials Announces Selection of Pharmaceutics International, Inc. as U.S. Manufacturer of...

PRFX : 2.97 (-7.19%)
PainReform to Present at Dawson James Securities 6th Annual Small Cap Growth Conference on October 21, 2021

TEL AVIV, Israel, Oct. 14, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty...

PRFX : 2.97 (-7.19%)
PainReform Provides Business Update for the Second Quarter of 2021

Shifting manufacturing and scale up operation to U.S.-based Contract Development and Manufacturing Organization for PRF-110

PRFX : 2.97 (-7.19%)
PainReform Provides Business Update for the First Quarter of 2021

Reports continued progress towards start of Phase 3 trials

PRFX : 2.97 (-7.19%)

Business Summary

PainReform Ltd.is a clinical stage specialty pharmaceutical company. It engages in the development of products for the treatment of pain. The company's product pipeline includes PRF-110, a product based on local anesthetic ropivacaine, which is in clinical stage. PainReform Ltd.is based in Herzeliya,...

See More

Key Turning Points

3rd Resistance Point 3.87
2nd Resistance Point 3.50
1st Resistance Point 3.24
Last Price 2.97
1st Support Level 2.61
2nd Support Level 2.24
3rd Support Level 1.98

See More

52-Week High 80.64
Fibonacci 61.8% 50.50
Fibonacci 50% 41.18
Fibonacci 38.2% 31.87
Last Price 2.97
52-Week Low 1.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar